4BASEBIO UK SOCIETAS (4BB) - Total Assets
Based on the latest financial reports, 4BASEBIO UK SOCIETAS (4BB) holds total assets worth GBX29.55 Million GBX (≈ $3.60K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
4BASEBIO UK SOCIETAS - Total Assets Trend (2019–2025)
This chart illustrates how 4BASEBIO UK SOCIETAS's total assets have evolved over time, based on quarterly financial data. Also see 4BB stock market capitalisation for the company's overall valuation and market capitalisation.
4BASEBIO UK SOCIETAS - Asset Composition Analysis
Current Asset Composition (December 2025)
4BASEBIO UK SOCIETAS's total assets of GBX29.55 Million consist of 69.9% current assets and 30.1% non-current assets. Review 4BASEBIO UK SOCIETAS (4BB) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 60.3% |
| Accounts Receivable | GBX289.00K | 1.0% |
| Inventory | GBX657.00K | 2.2% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX4.83 Million | 16.3% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how 4BASEBIO UK SOCIETAS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 4BB stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 4BASEBIO UK SOCIETAS's current assets represent 69.9% of total assets in 2025, an increase from 51.8% in 2019.
- Cash Position: Cash and equivalents constituted 60.3% of total assets in 2025, up from 6.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, a decrease from 38.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 16.3% of total assets.
4BASEBIO UK SOCIETAS Competitors by Total Assets
Key competitors of 4BASEBIO UK SOCIETAS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
4BASEBIO UK SOCIETAS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.31 | 11.30 | 19.08 |
| Quick Ratio | 7.07 | 11.18 | 18.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX17.84 Million | GBX33.62 Million | GBX14.70 Million |
4BASEBIO UK SOCIETAS - Advanced Valuation Insights
This section examines the relationship between 4BASEBIO UK SOCIETAS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.35 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -33.9% |
| Total Assets | GBX29.55 Million |
| Market Capitalization | $1.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values 4BASEBIO UK SOCIETAS's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 4BASEBIO UK SOCIETAS's assets decreased by 33.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 4BASEBIO UK SOCIETAS (2019–2025)
The table below shows the annual total assets of 4BASEBIO UK SOCIETAS from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX29.55 Million ≈ $3.60K |
-33.93% |
| 2024-12-31 | GBX44.73 Million ≈ $5.44K |
+275.16% |
| 2023-12-31 | GBX11.92 Million ≈ $1.45K |
+1.99% |
| 2022-12-31 | GBX11.69 Million ≈ $1.42K |
-20.49% |
| 2021-12-31 | GBX14.70 Million ≈ $1.79K |
-17.45% |
| 2020-12-31 | GBX17.81 Million ≈ $2.17K |
+1441.90% |
| 2019-12-31 | GBX1.16 Million ≈ $140.53 |
-- |
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for u… Read more